Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What a run from the $7's a few months back. Closed my entire position on Tuesday. Sitting on powder ready to go. ARDX looking really strong right now coming off its lows with some upcoming catalyst.
I was hoping for $5. more a share but a win is a win haha
Nice! patience always pays. Agree it will lose some steam quickly. Half my position is gone, will add if it goes back down below $13's. Hopefully it does get a bigger offer, but not waiting for that to happen.
Followed
Lol. No worries it will make a comeback. Even though management is quite, they need the share price up. They're options are worthless at this point. Just need to be patient. Good Luck!
I also took profits on most of the shares I owned I have been in this for quite awhile at $21.40 I always thought Pfizer would buy this but when I read Sumo said they would not sell their shares that changed my thinking. I didn’t make much for the amount of time I held but I was under water for along time wondering if I would just break even. If they don’t raise their bid this will crash
Yep taking profits here as don't want to be burned like with AUPH.
Taking more off the top. What a great day here!
The tell in that sad situation was the insider sales near the top. (Wish I had paid more attention to that, major lesson learned)
What we will see is if Pfizer wants to partner with Sumo or do they want the whole thing. If so they have to buy all the shares and Sumo will be in the drivers seat . Should become interesting
Sorry to hear that I don’t think this is the same situation. They low balled probably knowing it wouldn’t fly, there are 3 Sumo people on Myov board. They will sweeten the offer now how much who knows but we will see soon enough
I have tried to put all the details of that sordid story behind me, but basically last Fall, Bristol Meyers was set to buy Aurinia. Financial officer released the story and then quickly erased it and was later fired, but ultimately the CEO thought the deal was not good enough and things went south from there. Then of course sales of their very expensive drug have gone nowhere and stock cratered to 1/5 of supposed deal price.
Not aware of that what happened
Hope there is no screw up like Peter Greenleaf with Aurinia.
That would value around 2.3 billion no way too cheap they know it
Maybe. The problem (for MYOV minority shareholders) is that Sumitovant can play hardball and force the issue if they choose to do so.
It is just getting started first volley they already turned it down. They will be coming back higher and hopefully this will get Pfizer off the fence. Getting interesting
https://finance.yahoo.com/news/myovant-sciences-special-committee-board-233600693.html
I warned against exactly this kind of “takeunder” in #msg-167606619.
I believe they want to be taken over now they might not want a hostile takeover but why do we care if SP goes up
Either way they are going to make a killing. What a great position to be in. They keep adding shares too. As long as it is not a hostel takeover, that would be catastrophic for retail.
Yes Sumo owns 53% and has 3 board members so it will be their decision. So if Pfizer does want it at $40 to $50 a share that is a lot of cash for Sumo. Otherwise they will have to wait until myovant grows their revenue and turns profitable.
With Sumitomo owning the majority of shares it will be up to them if they want to sell or not.
With their share count at around 100 million approximately 5 billion buyout definitely in Pfizer’s wheelhouse
So you are looking for a BO at close to $50 per share?
Yes Sumo owns majority and some people think they will eventually buy the rest but I’m not in that camp. I think Pfizer will be the suitor. They are in the buying mode in that 5 billion range which myov will fall into imo
Sumitomo owns most of the shares, so there is hardly any shares for the public. Price can really move with little volume. The increasing revenue and recent nod from FDA also a factor. The partnership with PFE was a great idea, the long arms of BP can really move a product.
Took a little more off the table today. MYOV! $7 back in May, what a nice come back from yearly low.
Listened to the conference yesterday seemed run of the mill no questions or mention of buyout. Sure didn’t explain run any theories here?
Difficult to believe we wouldn't see 52 week highs. Another approval and sales climbing.
Nice break to the upside!
Consolidating the past few weeks. Which way is it going to break....
Took some profits today. Looking really bulllish!
Any guess as to what to expect in premarket Monday?
Glad I swung my AUPH money over here a couple of weeks ago adding to my position here I started in the Spring.
MYFEMBREE FDA Approved! Looking forward to Monday!
Those bargain prices from a few months back is up 70%!
If volume comes back this will blast off.
MYOV!
Go baby go!! MYOV! Going up on really low volume. Not sure if we can hold these gains.
The deal terms were not better than expected, so the sell-off is not especially surprising on a day like today.
Good news does nothing in fearful market. 7's...wow, trading like phase 2 company with no FDA approved drugs.
I'm holding bags for sure lol
MYOV bags European partner for Orgovyx:
https://www.globenewswire.com/news-release/2022/05/09/2438369/0/en/Myovant-Sciences-and-Accord-Healthcare-Ltd-Enter-into-Exclusive-License-Agreement-to-Commercialize-ORGOVYX-for-Advanced-Hormone-Sensitive-Prostate-Cancer-in-Europe.html
Myovant Sciences and Accord Healthcare, Ltd. (Accord) today announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland and Turkey…
…Under the terms of the agreement, Myovant will receive an upfront payment of $50 million and is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million. In addition, Myovant is eligible to receive tiered royalties from the high-teens to mid-twenties on net sales.
Cheers Bro! buying the dip in both
Cosa,
I see you are also into MYOV. I no longer post on AUPH as I am tired of BR, Cervelo, Whalatane, and Rosemount bomber, who I suspect are all questionable posters and now dominate a once good site. I was there due to Vidpok. You, zzaatt, and moosedogger would probably appreciate stocktwits AUPH much more. There is a good amount of fud posters but also some serious posters also that dig up much more good info. Just wanted to let you know.
Winepro1, ( aka HarryCrumb).
I think you're taking the smarter approach. I'm putting myself in a higher risk higher reward situation. Nothing a few drinks can't fix lol.
Hoping I don’t miss the boat but I’m waiting for the FDA letter
Market cap below $1B. 2 year low. I bought more at $9.64 averaging down. Back in 2019 it went from high of $26 down to $4.50. I wonder if that is going to this year. Bio's keep getting hammered.
There is still time for the FDA to deliberate about the problem in question between now the 5/6/22 PDUFA date.
“The FDA noted that the letter does not reflect a final decision on the pending sNDA and that the application is still under review”
Any thoughts on why the FDA has not yet given a final decision?
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
195
|
Created
|
11/02/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |